Evidence map›Paper›PMID 36002910›Full record

ArticleJournal of the International AIDS Society2022

A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe.

Janan Janine Dietrich, Nadia Ahmed, Emily L Webb, Gugulethu Tshabalala, Stefanie Hornschuh, Mamakiri Mulaudzi, Millicent Atujuna, Lynda Stranix-Chibanda, Teacler Nematadzira, Andrew Sentoogo Ssemata and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06133686 (Implementing Oral), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06133686 phase3not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa: a Phase 3b, Open-label, Hybrid Type 2 Implementation and Effectiveness Trial

TypeinterventionalSponsorMRC/UVRI and LSHTM Uganda Research UnitRan2024 to 2027Enrolled400ConditionsHIVArmsTenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA), Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 5 countries.

Janan Janine DietrichPerinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-1949-3138
Nadia AhmedMortimer Market Centre, Central North West London NHS Trust, London, United Kingdom.
Emily L WebbMRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Gugulethu TshabalalaPerinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Stefanie HornschuhPerinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Mamakiri MulaudziPerinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Millicent AtujunaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-1287-2634
Lynda Stranix-ChibandaClinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.ORCID 0000-0003-3566-1688
Teacler NematadziraClinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
Andrew Sentoogo SsemataMedical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.ORCID 0000-0003-0060-0842
Richard MuhumuzaMedical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Janet SeeleyMedical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.ORCID 0000-0002-0583-5272
Linda-Gail BekkerDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0755-4386
Helen A WeissMRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-3547-7936
Neil MartinsonPerinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Julie FoxGuys and St Thomas' NHS Trust/King's College London, London, United Kingdom.
CHAPS team
University of the Witwatersrand · ZALondon School of Hygiene & Tropical Medicine · GBDesmond Tutu HIV Foundation · ZAUganda Virus Research Institute · UGUniversity of Zimbabwe · ZWCentral and North West London NHS Foundation Trust · GBKing's College London · GBSouth African Medical Research Council · ZA

Funding

Medical Research Council MC_UU_00027/4Medical Research Council MR/R010161/1
6 · The paper itself

Abstract

introductionSub-Saharan Africa (SSA) carries the burden of the HIV epidemic, especially among adolescents and young people (AYP). Little is known about pre-exposure prophylaxis (PrEP) uptake and preferences among AYP in SSA. We describe preferences for daily and on-demand PrEP among AYP in South Africa, Uganda and Zimbabwe.

methodsA cross-sectional survey was conducted in 2019 among 13- to 24-year olds, capturing socio-demographics, HIV risk behaviours and preferences for daily or on-demand PrEP. Logistic regression models were used to estimate odds ratios, adjusting for site, sex and age. RESULTS AND DISCUSSION: A total of 1330 participants from Cape Town (n = 239), Johannesburg (n = 200), Entebbe (n = 491) and Chitungwiza (n = 400) were enrolled; 673 (51%) were male, and the median age was 19 years (interquartile range 17-22 years). Of 1287 participants expressing a preference, 60% indicated a preference for on-demand PrEP with differences by site (p < 0.001), sex (p < 0.001) and age group (p = 0.003). On-demand PrEP was most preferred in Entebbe (75%), among males (65%) versus females (54%) and in older participants (62% in 18- to 24-year-olds vs. 47% in 13- to 15-year-olds). After adjusting for site, sex and age group, preference for on-demand PrEP decreased as sex frequency over the past month increased (p-trend = 0.004) and varied with the number of partners in the last 6 months, being least popular among those reporting four or more partners (p = 0.02). Participants knowing further in advance that they were likely to have sex were more likely to prefer on-demand PrEP (p-trend = 0.02). Participants having a larger age gap with their most recent partner and participants whose last partner was a transactional sex partner or client were both less likely to prefer on-demand compared to daily PrEP (p = 0.05 and p = 0.09, respectively). Participants who knew their most recent partner was living with HIV or who did not know the HIV status of their most recent partner were less likely to prefer on-demand PrEP (p = 0.05).

conclusionsOur data show that AYP in four SSA communities prefer on-demand over daily PrEP options, with differences seen by site, age and sex. PrEP demand creation needs to be reviewed, optimized and tailored to socio-demographic differences and designed in conjunction with AYP.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentAdultAgedCross-Sectional StudiesFemaleHumansInfant, NewbornMaleSouth AfricaUgandaYoung AdultZimbabweAnti-HIV AgentsAfricaHIVon-demandoral pre-exposure prophylaxisyoung people

Identifiers

PMID36002910
PMCPMC9402915
OpenAlexW4293101898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.